Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Ke Ih Kim"'
Autor:
Soo Ryang Kim, Soo Ki Kim, Hisato Kobayashi, Takako Fujii, Toyokazu Okuda, Atsushi Nakai, Yumi Fujii, Takanobu Hayakumo, Ryuji Suzuki, Aya Otani, Noriko Sasase, Ke-Ih Kim, Tsutomu Kumabe, Yu-ichiro Koma, Osamu Nakashima
Publikováno v:
Kanzo. 64:141-149
Autor:
Soo Ki Kim, Soo Ryang Kim, Yumi Fujii, Toyokazu Okuda, Takanobu Hayakumo, Atsushi Nakai, Hisato Kobayashi, Aya Otani, Ke-Ih Kim, Takako Fujii
Publikováno v:
Kanzo. 63:401-408
Autor:
Takakazu Matsushita, Hironori Tanaka, Soo Ki Kim, Osamu Nakashima, Hisato Kobayashi, Toyokazu Okuda, Tsutomu Kumabe, Soichi Kubo, Takanobu Hayakumo, Atsushi Nakai, Hiroshi Yasui, Aya Ohtani, Yu-ichiro Koma, Yumi Fujii, Akira Yamada, Ke-Ih Kim, Soo Ryang Kim, Motoko Sasaki, Takako Fujii
Publikováno v:
Kanzo. 62:765-769
Publikováno v:
YAKUGAKU ZASSHI. 139:1147-1153
The number of patients with chronic liver diseases is expected to decline due to progress in antivirus therapy, including direct-acting antivirals for hepatitis C and nucleot(s)ide analogues for hepatitis B. On the other hand, the number of patients
Autor:
Hayakumo T, Tanaka Y, Okuda T, Ogawa S, Kim Sk, Fujii T, Kobayashi H, Kim, Saijo Y, Takami M, Ke Ih Kim, Yuasa K, Nakao K, Fujii Y, Ohtani A, Nakai A
Publikováno v:
Annals of Clinical and Medical Case Reports.
Autor:
Tomoko Inada, Hiroaki Otsuki, Michiaki Myotoku, Yuko Takasu, Kengo Hosomi, Ke-Ih Kim, Yuki Sugita, Yumiko Hisai, Yoshiaki Okamoto, Norio Masumoto, Sachiko Komaki
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 44:363-369
Autor:
Hobyung Chung, Midori Ando, Takanori Ito, Kayo Seo, Toshiharu Sakurai, Yujiro Nozawa, Natsuko Kobayashi, Toshifumi Tada, Aya Ohtani, Ryuichiro Iwasaki, Soo Ki Kim, Yasuharu Imai, Tomonari Okudaira, Noritomo Shimada, Etsuko Iio, Keiichi Seki, Osamu Nakashima, Ken Kamata, Tadaaki Arizumi, Tomohiro Watanabe, Koji Joko, Hirofumi Izumoto, Michitaka Imai, Hiroshi Ida, Kenichi Harada, Yuka Saijo, Takayuki Iwamoto, Tomohiro Minami, Mamoru Takenaka, Takeshi Okanoue, Akito Iwanaga, Yasuko Umehara, Akemi Tsutsui, Shigeya Hirohata, Yoshitake Hayashi, Takashi Owaki, Shogo Kitahata, Eiji Tsubouchi, Hirokazu Chishina, Soo Ryang Kim, Osakuni Morimoto, Aya Fujinami, Chi Wan Kim, Miho Kaneto, Taisei Murakami, Ke Ih Kim, Koichi Takaguchi, Nobuhura Tamaki, Norihiko Fujita, Yasuhito Tanaka, Yoriaki Komeda, Tomoyuki Ninomiya, Masatoshi Kudo, Tetsuo Takehara, Takashi Kumada, Masashi Kono, Kunihiko Tsuji, Hiroki Sato, Sachiyo Kogita, Susumu Imoto, Hidenori Toyoda, Kazuto Fukuda, Mana Kobayashi, Kazuomi Ueshima, Seitetsu Yoon, Masayoshi Kage, Takumi Igura, Satoko Nakamura, Naoshi Nishida, Shinji Katsushima, Masato Kishida, Atsushi Hiraoka, Toru Ishikawa, Satoru Hagiwara, Takuya Nagano, Kosuke Minaga, Druckerei Stückle, Koichi Mizobuchi, Hidetaro Ueki, Kazuto Tajiri, Akihiro Deguchi, Yoshiyuki Sawai, Terasu Honma, Hironori Ochi, Masahiro Takita, Hideomi Tomida, Eri Morimoto, Hiroyuki Kokuryu, Masanori Nakahara, Keisuke Amano, Toshiaki Yoshida, Marie Ochi, Toyokazu Fukunaga, Yasushi Matsumoto, Tomonori Senoh, Yuji Miyamoto, Masashi Hirooka, Hideki Miyata, Toshiki Komeda, Takashi Hatae, Koichi Tsuneyama, Hiroka Yamago, Kenichiro Mori, Yoichi Hiasa, Airi Kato, Yoshitaka Yamaguchi, Yohei Koizumi, Tomoe Sano, Kojiro Michitaka, Hiroshi Ohashi, Yasunori Minami, Norihisa Yada, Toshihiko Aibiki, Namiki Izumi, Yutaka Horie, Yoshihiko Yano
Publikováno v:
Digestive Diseases. 35:I-VIII
Autor:
Yoshitake Hayashi, Ke Ih Kim, Aya Ohtani, Yoshihiko Yano, Airi Kato, Soo Ryang Kim, Kayo Seo, Susumu Imoto, Soo Ki Kim, Masatoshi Kudo, Eri Morimoto, Chi Wan Kim, Mana Kobayashi, Yuka Saijo
Publikováno v:
Digestive Diseases. 35:541-547
Background: Sofosbuvir plus ribavirin (RBV) therapy showed higher sustained virological response at 12 weeks after treatment (SVR12) than pegylated interferon (peg-IFN) plus RBV; however, liver function, fibrosis, and hepatocellular carcinoma markers
Autor:
Ke Ih Kim, Soo Ryang Kim
Publikováno v:
YAKUGAKU ZASSHI. 136:565-572
Clinical identity of nonalcoholic steatohepatitis (NASH) has established it as a chronic liver disease since the 1990s in the USA and in the 21st century in Japan, although its significance is not well recognized in Japanese society. It is characteri
Publikováno v:
YAKUGAKU ZASSHI. 136:583-589
Nonalcoholic fatty liver disease (NAFLD) is characterized by the pathological accumulation of fat in the liver in the absence of any other disease related to liver steatosis, which includes a wide spectrum of liver diseases ranging from mild asymptom